Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

57.1%

-29.4% vs industry average

Late-Stage Pipeline

71%

5 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3

4(57.1%)

Phase 2

2(28.6%)

Phase 4

1(14.3%)

7Total

Phase 3(4)

Phase 2(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT00130312Phase 4Terminated

Effect of Sulodexide in Overt Diabetic Nephropathy

Role: collaborator

NCT00130208Phase 3Completed

Effect of Sulodexide in Early Diabetic Nephropathy

Role: collaborator

NCT00648167Phase 2Completed

A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)

Role: collaborator

NCT00462202Phase 3Terminated

Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong

Role: collaborator

NCT02156843Phase 3Terminated

Pyridorin in Diabetic Nephropathy

Role: collaborator

NCT00734253Phase 2Completed

Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes

Role: collaborator

NCT01074125Phase 3Completed

A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease

Role: collaborator

All 7 trials loaded